Abstract-Heparan sulfate (HS) represents a large class of linear polysaccharides that are required for the function of all mammalian physiological systems. HS is characterized by a repeating disaccharide backbone that is subject to a wide range of modifications, making this class of macromolecules arguably the most information dense in all of biology. The majority of HS functions are associated with the ability to bind and regulate a wide range of proteins. Indeed, recent years have seen an explosion in the discovery of new activities for HS where it is now recognized that this class of glycans functions as co receptors for growth factors and cytokines, modulates cellular uptake of lipoproteins, regulates protease activity, is critical to amyloid plaque formation, is used by opportunistic pathogens to enter cells, and may even participate in epigenetic reg ulation. This review will discuss the current state of understanding regarding the specificity of HS-protein binding and will describe the concept that protein binding to HS depends on the overall organization of domains within HS rather than fine structure.
Heparin and HS are linear polysaccharides character ized by repeating disaccharide units of alternating N sub stituted glucosamine and hexuronic acid residues subject to selective modification including sulfation of the N posi tion as well as the C 6 and C 3 O positions of the glu cosamine and the C 2 O position of the uronic acid [1 3] (Fig. 1) . Thus, the 32 (or more) potential unique disaccha ride units and their grouping into structural motifs make this class of compounds one of the most information dense in biology [4 6 ]. Unlike proteins, the sequence and overall structure of these complex molecules are not defined by a template. Instead, the specific structure is the result of the action of at least 18 biosynthetic enzymes as well as the postsynthetic processing by 6 O sulfatases and heparanase [7] (Fig. 1) . While the structure of HS expressed by cells can rapidly change in response to specific conditions, the specific mechanisms controlling HS biosynthesis and post synthetic modification remain to be defined.
HS chains are found attached to core proteins in proteoglycans on cell surfaces and within the extracellu lar matrix (ECM) of nearly all mammalian cells and tis sues [2, 6] . On cell surfaces, HS is mainly found attached to two classes of core proteins, the syndecans and glypi cans. The syndecans (1 through 4) are characterized by a transmembrane core protein with HS and sometimes chondroitin sulfate chains attached to the region of the core protein extending from the cell surface into the peri cellular matrix [8] . Glypicans (1 through 6), on the other hand, are anchored to the plasma membrane via glyco sylphosphatidylinositol attached to a hydrophobic domain within the C terminal region with the HS chains restricted to the last 50 amino acids such that they are held close to the membrane [9] . There are several heparan sulfate proteoglycans (HSPGs) found within the ECM including perlecan, agrin, and collagen XVIII [10, 11] . It is generally believed that the biological function of HSPGs are dependent on HS structure and localization of the HSPG, with cell surface HSPGs being implicated in controlling ligand-receptor interactions and ECM HSPGs being considered important modulators of inter cellular molecular traffic [12, 13] (Fig. 2) .
In contrast to HS, the highly sulfated and more structurally uniform heparin is stored almost exclusively in the granules of cells of hematopoietic lineage, includ ing connective tissue mast cells, as part of large heparin proteoglycans that function to package inflammatory proteases [14 17 ]. In addition, a highly sulfated form of
HS is present in leukocytes [18] . Heparin has been used clinically as an anti coagulant for ~80 years and has also been shown to have anti inflammatory activity and both anti and pro angiogenic activities [19 22] . The wide range of activities attributed to heparin and HS probably reflects the large number of proteins that these gly cosaminoglycans bind and modulate [23 25] . While the majority of disaccharides within heparin contain 2 O, 6 O, and N sulfate groups, HS is more structurally diverse with protein binding sites more selectively expressed [23, 25] . Because of this structural diversity, it is thought that changes in HS as a function of environmental stimuli (e.g. tissue injury, ischemia) may lead to regulation of cel lular responses to important extracellular proteins through alterations in HS-protein binding.
HS is essential for embryonic development [26] and required for the function of all adult physiological sys tems. HS structure and expression can change rapidly during development [26 28] , indicating that alterations in HS might be a key signal of functional changes in cells and tissues. While the complete mechanisms remain unknown, it is generally believed that HS function is mediated by the ability of HS to bind and regulate pro teins. A recent bioinformatics analysis of the HS interac tome identified 435 human proteins that interact with HS or the structurally related heparin [29] . Network analysis of HS binding proteins revealed enrichment in processes such as cell-cell communication, wound healing, immune response, defense response, and regulation of cell proliferation. Not surprisingly, HS has been implicat ed in many human diseases including cardiovascular dis ease, chronic obstructive pulmonary disease, cancer, infectious disease, amyloidosis, and HIV/AIDS [30 41 ]. As such, there are a number of drugs currently in devel opment that aim to either interfere with or replicate the protein binding/regulating function of HS. The motiva tion for the development of HS based drugs is driven in part by the long standing clinical success of unfractionat ed and low molecular weight heparin as well as anecdot al evidence of secondary benefits of heparin unrelated to antithrombotic activities [32 34, 42] . While recent research has produced considerable insight, the chemical mechanisms underlying HS-protein binding affinity and specificity remain to be fully defined. Thus, the aim of this review is to evaluate the current state of understand ing of the structural specificity that underlies HS-protein binding by discussing a few specific examples in detail.
HEPARAN SULFATE-PROTEIN BINDING
Based on the finding that antithrombin III binds specifically to a rare pentasaccharide sequence present in heparin, early models proposed the existence of protein specific binding site sequences encoded within the pri mary structure of HS [43] . However, recent findings indi cate that the formal binding site sequence specificity of antithrombin III is the exception and not the rule. Instead, a model has been proposed where proteins bind to localized sulfate rich domains (NS domains) that are distributed throughout the HS chain separated by inter vening under sulfated regions (NA domains) [23, 24] . While short sulfated oligosaccharides (degree of polymer ization (dp) 4 8) have been isolated to support this con cept, full biological activity generally requires longer HS chains with more complex structure [5, 6] .
Consistent with the concept that positioning of sul fate residues is critical for protein binding, most heparin binding proteins have clusters of basic amino acid residues that have been shown to be required for binding heparin [43] . However, an energetic analysis of heparin-protein binding using isothermal calorimetry indicates that ~70% of the binding energy involves non ionic interactions such as hydrogen bonds and van der Waals forces [44] . This analysis, like most previous stud ies on HS-protein binding, used highly sulfated heparin as a model for HS, which may have biased the data toward identifying important ionic interactions because of the nearly uniform highly sulfated structure of heparin. Thus, it is likely that intervening NA domains function as more than simple spacer regions and instead might participate directly in protein binding.
Work by our group has also noted that a range of heparin binding growth factors can compete for one another's binding to large capacity but low affinity sites on HS while also showing specific high affinity binding to low density binding sites [45, 46] . These findings are beginning to indicate that protein binding to HS is nei ther purely discrete and specific nor general and nonspe cific. Instead a concept has been emerging whereby HS activity reflects the composite of its ability to bind a range of proteins in a variety of ways with some binding events leading to specific tight complexes while others providing a means to modulate protein availability and movement within the peri and extracellular space (Fig. 2) .
In a recent elegant study, FGF2 (fibroblast growth factor 2) movement within the pericellular matrix was tracked using single molecular imaging to produce com pelling evidence that binding sites on HS chains are arranged in a nonrandom heterogeneous network [47] . As such, FGF2 movement appears to involve translocation from one HS binding site to another where the rate of movement apparently relates to the distribution and the selectivity of these binding sites. Indeed, previous studies from our group concluded that a binding and diffusion model effectively describes the transport of growth factors within isolated basement membrane [48] .
HS CONTROL OF FIBROBLAST GROWTH FACTOR 2
Fibroblast growth factors (FGFs) represent a large family of related proteins that bind to heparin and HS and show a wide range of important biological activities including regulation of cell proliferation, migration, dif ferentiation, and tissue morphogenesis [49, 50] . The involvement of HS in the FGF system has been studied extensively and now represents a classic mechanism by which HS can modulate protein-protein interactions [51] . Although the majority of these studies focused on the role of HS in modulating FGF1 and FGF2, the fun damental mechanism has now been extended to under stand other FGF family members as well as other heparin binding growth factors. HS has been shown to play a key role as a co receptor that stabilizes FGF-FGF receptor (FGFR) complex formation through interac tions with both proteins. While studies have shown that short (dp 6 8) heparin or HS derived oligosaccharides are sufficient to bind and promote FGF2 activity, longer HS chains containing significantly reduced overall sulfate density are more active in mole/mole comparisons with high affinity FGF2 binding oligosaccharides [52, 53] . These observations indicate that longer chains may con tain structural functionality that is required for activity and that NA domains comprise a portion of the protein binding sites. One possibility is that spacer regions act to properly position multiple sulfate rich domains for bind ing to FGF and its receptor proteins to enhance binding avidity. It has also been suggested that longer HS chains are required for the formation of higher order multimer ic complexes of FGF-FGFRs on the cell surface [53] .
There remains considerable debate over the nature and stoichiometry of the active complexes, with data supporting various models of FGF-FGFR-HS complexes (i.e. 2 : 2 : 1, 2 : 2 : 2, 4 : 4 : 2) [54 58 ]. We propose that there are mul tiple competent complexes whose signal intensity and duration may depend on the nature of the HS chain and the specific complex type that forms. For instance, our previ ous data indicate that proteoglycans containing multiple HS chains that localize to lipid raft domains may be able to capture and retain FGF2 to enhance prolonged FGFR sig naling [59, 60] . In this regard, we have also shown that FGF2 binds to multiple classes of binding sites within HS, with some being non selective and low affinity sites but present at very high levels, and others being more specific high affinity sites but rare [45] . Recently we isolated FGF2 binding hexasaccharides from a library generated from HS using SEC (size exclusion chromatography) fol lowed by hydrophobic trapping and MS, and characterized low and high affinity binders [52] . The low affinity sites were mostly derived from internal regions of the HS chain, whereas the high affinity sites were enriched in non reduc ing end NS domains. We also noted that the high affinity binders were selectively more active at promoting FGF2 induced cell proliferation using a BaF32 cell system. These results support a 1 : 1 ratio model for HS chains in the FGF system, where high affinity NS sites at the non reducing end might selectively participate in the formation of high affinity FGF ternary complexes (Fig. 2) .
Longer chains may also be required to enhance lig and-receptor interactions through nonspecific low affinity interactions with under sulfated regions that may increase FGF-FGFR encounter frequency [46, 60, 61] . While the structural requirements for heparin-FGF binding have been described and receptor specificity has been defined for the FGF system's 23 ligands and seven receptor variants [62, 63] , there remains little known about the HS structural requirements for interaction with FGF receptors or how distinct domain organization with in HS can modulate FGF-FGFR complex formation. Similar gaps in knowledge exist for a wide range of heparin binding protein systems. Thus, the ability of HS to participate in other growth factor-receptor systems, modify protease activity, alter protein structure, and mediate enzyme-substrate association is likely to be dependent on higher order HS structure, yet to date there have been frustratingly few methods available to allow for the study of HS function at this level.
HS MEDIATED PROTEASE INHIBITION IN EMPHYSEMA
Chronic obstructive pulmonary disease (COPD), which includes emphysema, is the fourth leading cause of Fig. 3 . Inhibition of neutrophil elastase by heparan sulfate. a) Space filling structures for human neutrophil elastase based on the solved X ray crystal structure 1HNE [108] , and for a heparin derived dodecasaccharide based on NMR analysis (1HPN) [109] . b) The relative rate of human neutrophil elastase digestion of a pseudosubstrate N Suc (Ala) 3 pNA in the presence of the indicated heparin derived oligosaccharide. Degree of polymerization is indicated on the x axis. Reactions were carried out for 1 h at 27°C. Experimental details of elastase enzyme assay conditions are described in [70] . Increasing length death in the United States, accounting for more than 120,000 deaths in 2007 [64] . COPD comprises multiple disease types including chronic bronchitis and emphyse ma. Emphysema, in particular, is characterized by pro gressive destruction of elastin within the lung leading to airspace enlargement, decreased tissue compliance, and reduced gas exchange. Seminal findings, first reported in the 1960s, identified a strong link between emphysema and a deficiency in the natural protease inhibitor, α 1 anti trypsin (AAT), leading to the hypothesis that this disease is the result of an imbalance between proteases and antiproteases [65, 66] . Since these initial observa tions, a preponderance of evidence has implicated leuko cyte derived elastases as major culprits in emphysema. For example, mice deficient in neutrophil elastase show 60% reduced airspace enlargement compared with wild type counterparts in response to cigarette smoke [67] . Hence, there is strong interest in understanding how to best regulate the levels and activities of proteolytic enzymes such as neutrophil elastase within the lung. Consequently, considerable effort has been directed toward producing effective elastase inhibitors to treat emphysema [68, 69] , yet to date, none have proven to be clinically effective.
In addition to natural protein based inhibitors of neutrophil elastase, heparin and HS have been shown to bind and inhibit this enzyme [70, 71] . In the lung, HS has been shown to play critical roles in development [28, 72, 73] , to be targets of elastase, and to participate in ECM assembly [74 82 ]. Indeed, heparin and HS inhibit elas tase mediated airspace enlargement in mice [83, 84] . While it appears that HS is involved in the lung response to elastase at many levels, there remain considerable gaps in our understanding of the specific mechanisms of these processes. More generally it is interesting to note that HS has been implicated as a modulator of multiple mediators of lung injury that underlie the pathogenesis of emphyse ma. For example, HS has been suggested to provide pro tection against oxidative stress directly [85] and through interactions with extracellular superoxide dismutase (ecSOD) [86 88 ], store and protect vascular endothelial growth factor and facilitate its receptor activation [89 93 ], inhibit elastase activity [70, 83, 84, 94] , control cell-ECM adhesion [95 98 ] and contribute to the mechanical properties and stability of the alveolar wall [99] , and potentially influence chromatin structure through alterations in histone acetylation [100] .
Work by our group has focused on the inhibition of elastase by heparin and HS [70] , with the goal of under standing how natural feedback mechanisms involving HS within the lung might normally be involved in limiting elastase activity. Moreover, the ability of elastase to release HS has a number of consequences with regard to the stor age and release of critical regulatory growth factors such as FGF2, transforming growth factor β, and heparin binding epidermal growth factor [77, 78, 101 105] .
Our analysis of heparin/HS inhibition of elastase revealed that heparin acts as a hyperbolic, tight binding competitive inhibitor of elastase as indicated by an increase in K m with no change in V m and incomplete inhi bition of activity even in the presence of high heparin concentrations [70] . We further established that the chemical structure of heparin is critical for inhibition as a minimum length of 12 monosaccharide residues was required for activity, and selectively de sulfated heparin preparations were less active (Fig. 3) . These length requirements were consistent with molecular docking studies that indicated that relatively long HS chains would be required to bridge the entire elastase molecule [70] . Interestingly, we and others have shown that HS can inhibit elastase, yet it is unlikely to ever have such long stretches of highly sulfated heparin like domains, sug gesting that contiguous NS domains are not required for inhibition. Instead, we have proposed, based on structur al analysis of elastase inhibitory HS, that optimal inhibi tion may require two separate NS domains separated and properly spaced by an under sulfated region [106] . Because an extended NS domain has been found as a general feature of HS chains regardless of organ source [107] , there may be implications of such domains for elas tase regulation.
DETERMINING HS DOMAIN STRUCTURE
Although it was initially thought that specific sequences within HS would prove to be responsible for the ability to bind and modulate the wide array of heparin binding proteins, it is now thought that the par ticular arrangement and spacing of structural domains may underlie HS activity [25] . While it is clear that the complex structure of HS underlies the ability to bind and modulate protein function, technology for determining how HS structure defines function remains lacking. Despite the common analytical procedures that exist to sequence nucleic acids and proteins, the ability to fully characterize HS remains elusive. We suggest that this is due to the unique level of complexity and non template driven biosynthesis that makes HS resistant to traditional approaches used to define biological polymers. Thus, fundamental understanding of HS biochemistry will require a different conceptual model. Whereas the func tion of a given protein can be evaluated based on its unique folded structure, it appears that the function of HS emerges from the arrangement and density of partic ular domain patterns (i.e. local arrangement of various sequence clusters).
As analytical methods have advanced to the point that complete HS compositional information can be produced in high throughput, the need for new bioinformatics algo rithms to model HS structure has become critical. To meet this need, our lab recently developed the foundation of a BIOCHEMISTRY (Moscow) Vol. 78 No. 7 2013 computational method, the ChainMaker Program (ChamP), for deciphering the domain pattern and sequences of complex mixtures of HS chains based on di saccharide compositional analysis [106] (Fig. 4) . ChamP uses disaccharide composition data in conjunction with known biosynthetic rules to model the overall structures of a population of HS chains. This process begins with complete digestion of HS with heparin lyases I, II, and III to obtain the overall composition of the major disaccha rides. HS samples are also subjected to selective and sequential digestion with these enzymes, and the release of each disaccharide is measured as a relative fraction of the total. Then, based on defined substrate cleavage speci ficities for the various heparin lyases, ChamP produces populations of theoretical HS chains with structures that match the compositional data and meet biosynthetic rules. Each chain is then subjected to a chain breaker rou tine where it is digested with the various heparinase enzymes alone and in sequence in silico, and theoretical disaccharides released are compared with those measured experimentally. Chains that do not produce degradation profiles matching those measured experimentally are dis carded, and the process is repeated until a sufficient num ber of unique chains are produced (generally 100 200 chains). The final population of HS chains provides a rep resentation of the mixed biological population that can be evaluated and sorted for any property of interest. For instance, the output chains can be searched for a specific sequence or general characteristic that may impart func tion. Measured values for glucuronic versus iduronic acid residues from deaminative cleavage as well as chain length distribution can also be included as part of the ChamP input to improve the accuracy of the output chains.
HS is involved in nearly every cellular process at some level where it appears to function as a critical tuning factor that can enhance or attenuate the activity and/or dynamics of a wide range of bioactive proteins. It is gen erally accepted that this wide range of functions is encod ed within HS structure, yet how HS structure is con trolled by cells as a means to modulate protein interac tions and activity remains poorly understood. Moreover, the standard paradigm in biochemical research of isolat ing an active factor from a complex mixture of molecules may not translate well to HS where the density and spe cific arrangement of "active" motifs within a given chain and within a population of chains may ultimately dictate biological function. Therefore, expansion of new and emerging technologies is needed to allow populations of HS chains to be defined based on their domain structure in order to gain insight into how HS is used by cells and tissues to maintain homeostasis and to respond to envi ronmental challenges.
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